Pancreatic Cancer Research

ResearcherMie UniversityActive in the last 2 years

Takahiro Ito

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1876-3052; OpenAlex author ID A5101423845. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
18
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 3 papers · 2023: 1 paper · 2024: 2 papers · 2025: 5 papers

Papers 12

  1. Long-term survival analysis based on tumor location in patients with pancreatic ductal adenocarcinoma who underwent pancreatectomy following neoadjuvant chemor… Co-author DOI 10.1007/s00423-025-03609-8↗
  2. Surgical strategies for locally advanced pancreatic cancer following gemcitabine plus S-1-based chemoradiotherapy. Co-author DOI 10.1016/j.suronc.2025.102269↗
  3. Prognostic impacts of biological and conditional factors in patients with anatomically resectable pancreatic adenocarcinoma treated with preoperative chemoradi… Co-author DOI 10.1097/md.0000000000042441↗
  4. Tumor Budding Is an Independent Adverse Prognostic Factor of Pancreatic Ductal Adenocarcinoma Patients Treated by Resection After Preoperative Chemoradiotherap… Co-author DOI 10.1097/mpa.0000000000002440↗
  5. Impact of Surgical Resection After Induction Gemcitabine Plus S-1-Based Chemoradiotherapy in Patients with Locally Advanced Pancreatic Ductal Adenocarcinoma: A… Co-author DOI 10.3390/cancers17061048↗
  6. Peritoneal washing cytology status as a crucial prognostic determinant in patients with localized pancreatic ductal adenocarcinoma who underwent curative-inten… Co-author DOI 10.1371/journal.pone.0309834↗
  7. Insight from Lymphocyte-Albumin Scores into Treatment Continuity of Nanoliposomal Irinotecan With 5-Fluorouracil and L-leucovorin in Metastatic Pancreatic Canc… Co-author DOI 10.21873/invivo.13768↗
  8. Extrapancreatic extension is a better adverse prognostic factor than tumor size in patients with localized pancreatic ductal adenocarcinoma treated with chemor… Co-author DOI 10.1016/j.hpb.2023.06.015↗
  9. Concomitant splenic artery ligation has no preventive effect on left-sided portal hypertension following pancreaticoduodenectomy with the resection of the port… Co-author DOI 10.1002/ags3.12545↗
  10. Predictive risk factors for early recurrence in patients with localized pancreatic ductal adenocarcinoma who underwent curative-intent resection after preopera… Co-author DOI 10.1371/journal.pone.0264573↗
  11. Involvement of superior mesenteric vein and superior mesenteric artery is adverse prognostic factors in patients with localized pancreatic ductal adenocarcinom… Co-author DOI 10.21203/rs.3.rs-2229927/v1↗
  12. Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locall… Co-author DOI 10.1097/mpa.0000000000001022↗

Closest collaborators

The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yasuhiro Murata · 11 shared papers, 2018–2025 · strength 1.93
  2. Aoi Hayasaki · 11 shared papers, 2018–2025 · strength 1.93
  3. Shugo Mizuno · 11 shared papers, 2018–2025 · strength 1.93
  4. Naohisa Kuriyama · 11 shared papers, 2018–2025 · strength 1.93
  5. Masashi Kishiwada · 11 shared papers, 2018–2025 · strength 1.93
  6. Kazuyuki Gyoten · 8 shared papers, 2022–2025 · strength 1.42
  7. Benson Kaluba · 6 shared papers, 2022–2025 · strength 1.14
  8. Toru Shinkai · 4 shared papers, 2022–2025 · strength 0.69
  9. Hiroyuki Sakurai · 3 shared papers, 2018–2022 · strength 0.36
  10. Shuji Isaji · 3 shared papers, 2018–2023 · strength 0.35
  11. Kazuo Matsubara · 1 shared paper, 2024 · strength 0.24
  12. Reiko Ashida · 1 shared paper, 2024 · strength 0.24
  13. Manabu Kawai · 1 shared paper, 2024 · strength 0.24
  14. Takuya Yuge · 1 shared paper, 2024 · strength 0.20
  15. Miki Usui · 1 shared paper, 2025 · strength 0.20
  16. Masatoshi Watanabe · 1 shared paper, 2025 · strength 0.20
  17. Yoshinori Azumi · 1 shared paper, 2018 · strength 0.07
  18. Hiroyuki Kato · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.